ST. LOUIS and PESSAC, France, Nov. 05, 2019 (GLOBE NEWSWIRE) — Stereotaxis (NYSE American: STXS) and inHEART today announced the first patients have been successfully treated with the integration of inHEART’s advanced preoperative mapping and Stereotaxis’ Robotic Magnetic Navigation technologies.
inHEART applies advanced algorithms on preoperative CT and MRI images to generate highly detailed three-dimensional maps of the heart. These maps display key structural information on the cardiac chambers, epicardium, coronary vasculature, phrenic nerves, and arrhythmogenic substrate. This information aids physicians in diagnosing the source of irregular heartbeats and planning cardiac ablation procedures. The latest version of Stereotaxis software, recently cleared for use in Europe and by the FDA, utilizes a software interface that integrates inHEART’s maps, cleared for use in Europe, and allows physicians to utilize them to guide robotic cardiac ablation procedures. The first integrated procedures were successfully conducted by Dr. Riho Luite of Kuopio University Hospital in Kuopio, Finland.
“Understanding the unique structural characteristics of each patient’s heart is valuable in designing optimal individualized therapy,” said Dr. Riho Luite. “The next challenge arises in delivering therapy to the appropriate areas of interest, particularly in hearts that have unusual anatomies or in chambers that have complex internal structures. The unmatched catheter reach and precision provided by Stereotaxis robotic technology combined with the roadmap provided by inHEART simplifies procedures and helps provide the best possible care for patients.”
“We are really excited about this successful combination of inHEART’s high resolution mapping with Stereotaxis’ robotic precision,” said Dr. Jean-Marc Peyrat, inHEART CEO. “This is a first step towards leveraging the full potential of combining both technologies to ease and standardize these complex interventions, and eventually to make effective cardiac catheter ablation accessible to most patients.”
“Stereotaxis is committed to advancing a robust open ecosystem where physicians and patients benefit from the broad integration of procedure data,” said David Fischel, CEO of Stereotaxis. “We are excited to be working with inHEART. Increased use of advanced preoperative imaging supports personalized patient-specific therapy, and in combination with robotics is a step forward in the digitization of interventional medicine.”
inHEART is a leader in image-based preoperative 3D mapping for cardiac ablation procedures. inHEART’s vision is to bridge the gap between medical imaging and cardiac electrophysiology to advance the treatment of cardiac arrhythmias to the next level with simpler, faster, and more standardized ablation procedures. inHEART has recently received regulatory clearance in Europe. For more information, please visit www.inheart.fr.
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis’ robotic technology has received various regulatory clearances in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
|David Fischel||Jean-Marc Peyrat, PhD, MBA|
|Chairman and CEO||CEO|
|Kimberly Peery||+33 5 35 38 19 72|